← Back to Search

Macrolide Antibiotic

Carrimycin for COVID-19

Phase 3
Waitlist Available
Research Sponsored by Shenyang Tonglian Group CO., Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline (day -4 to day -1) days 3, 7, 10, 14 and 28 after treatment
Awards & highlights

Study Summary

This study is evaluating whether a drug may help treat SARS.

Eligible Conditions
  • COVID-19

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline (day -4 to day -1) days 3, 7, 10, 14 and 28 after treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline (day -4 to day -1) days 3, 7, 10, 14 and 28 after treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to patient not requiring supplemental oxygen up to 28 days after randomisation
Secondary outcome measures
Change from baseline in respiratory rate
Change from baseline in temperature
Changes from baseline in sequential organ failure assessment (SOFA) score
+9 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CarrimycinExperimental Treatment1 Intervention
Patients will receive oral dose of 400 mg carrimycin once-daily and SOC for 14 days.
Group II: PlaceboPlacebo Group1 Intervention
Patients will receive oral dose of Placebo once-daily and SOC for 14 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carrimycin
2019
Completed Phase 1
~10

Find a Location

Who is running the clinical trial?

Shenyang Tonglian Group CO., LtdLead Sponsor
1 Previous Clinical Trials
520 Total Patients Enrolled
1 Trials studying COVID-19
520 Patients Enrolled for COVID-19

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
2021. "Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04672564.
~23 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top